Last reviewed · How we verify
NCT05036148: MHCZECH
Malignant Hyperthermia in Czech Republic: Description of the Biggest Slavonic Group of Patients Investigated for Risk of Malignant Hyperthermia
trial testing Data analysis in Malignant Hyperthermia in 286 participants. Completed in 31 December 2021.
31 December 2021
Quick facts
| Lead sponsor | Brno University Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 286 |
| Start date | 1 September 2021 |
| Primary completion | 31 December 2021 |
| Estimated completion | 31 December 2021 |
| Sites | 1 location across Czechia |
Drugs / interventions tested
- Data analysis — full drug profile →
Conditions studied
- Malignant Hyperthermia — all drugs for Malignant Hyperthermia →
Sponsor
Brno University Hospital
Who can join
Adults 1 Month to 99, any sex, with Malignant Hyperthermia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The Academic centre for Malignant Hyperthermia of Masaryk University (ACMHMU) was established in 2021 in Brno, Czech Republic and consists of four academic departments of Medical Faculty of Masaryk University in two tertiary university hospitals, University Hospital Brno and St. Anne Faculty Hospital. These departments collaborated and operated since 2002 and since 2019 is Brno one of the of centre of EMHG (www.emhg.org). Aim of this study was to describe the Czech and Slovak (CZ-SK) cohort of MHS patients, the biggest Slavonic MHS cohort known by now, and to fill the knowledge gap about the Slavonic population in perspective of MH.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Malignant Hyperthermia in Slavonic cohort - clinical and genetic findings beyond standard diagnostics.
Klincová M, Zídková J, Réblová K, Štěpánková D, et al · · 2026 · PMID 41913278 · DOI 10.1186/s13023-026-04339-w
Verify or expand the search:
- PubMed search for NCT05036148
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Data analysis
Trials testing the same drug.
- NCT05612230 — A Lifecourse Map of Diseases in China · unknown
- NCT05046275 — MCR Syndrome in Quebec : Results From NuAge Study · unknown
- NCT05056740 — Combined Analysis of Inflammatory Biomarkers for CNS Autoimmune Diseases Diagnostic · unknown
- NCT04323709 — Levosimendan for Veno-arterial ECMO Weaning · completed
- NCT03542864 — Medical Supervised Duodenal-Enteral Feeding Treatment · NA · completed
Other Brno University Hospital trials
Trials by the same sponsor.
- NCT07468006 — Comparison of Transcutaneous and Blood CO₂ Measurement in Critically Ill Children · recruiting
- NCT07280039 — Mortality and Muscle Mass Loss in Critically Ill Patients. · not yet recruiting
- NCT07279701 — The Effect of Near-infrared Spectroscopy on the Success of Peripheral Venous Access · NA · recruiting
- NCT07245654 — Monitoring the Depth of Anesthesia and Nociception During the Induction of General Anesthesia in Pediatric Patients · recruiting
- NCT07110012 — The Role of Simulation-based Training in Resident Curriculum in Anaesthesia and Intensive Care · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05036148 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Brno University Hospital
- Last refreshed: 15 April 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05036148.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing